Biogen gains MS candidate from Alkermes

On Nov. 27, Biogen Inc. (NASDAQ:BIIB) obtained an exclusive, worldwide license to commercialize multiple sclerosis candidate ALKS 8700 from Alkermes plc (NASDAQ:ALKS), removing a potential competitor to Biogen’s blockbuster MS drug Tecfidera dimethyl fumarate

Read the full 342 word article

User Sign In